DK3368044T3 - Behandling af hepatisk steatose-relateret oligo-ovulation - Google Patents

Behandling af hepatisk steatose-relateret oligo-ovulation Download PDF

Info

Publication number
DK3368044T3
DK3368044T3 DK16788501.1T DK16788501T DK3368044T3 DK 3368044 T3 DK3368044 T3 DK 3368044T3 DK 16788501 T DK16788501 T DK 16788501T DK 3368044 T3 DK3368044 T3 DK 3368044T3
Authority
DK
Denmark
Prior art keywords
steatose
ovulation
hepatic
treatment
related oligo
Prior art date
Application number
DK16788501.1T
Other languages
English (en)
Inventor
Zegher Francis De
Lourdes Ibáñez
Original Assignee
Univ Leuven Kath
Sant Joan De Deu Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leuven Kath, Sant Joan De Deu Hospital filed Critical Univ Leuven Kath
Application granted granted Critical
Publication of DK3368044T3 publication Critical patent/DK3368044T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16788501.1T 2015-10-27 2016-10-27 Behandling af hepatisk steatose-relateret oligo-ovulation DK3368044T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1518979.8A GB201518979D0 (en) 2015-10-27 2015-10-27 Treatment of hepatic steatosis related oligo-ovulation
PCT/EP2016/075953 WO2017072243A1 (en) 2015-10-27 2016-10-27 Treatment of hepatic steatosis related oligo-ovulation

Publications (1)

Publication Number Publication Date
DK3368044T3 true DK3368044T3 (da) 2021-09-13

Family

ID=55130283

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16788501.1T DK3368044T3 (da) 2015-10-27 2016-10-27 Behandling af hepatisk steatose-relateret oligo-ovulation

Country Status (24)

Country Link
US (2) US20190060328A1 (da)
EP (2) EP3368044B1 (da)
JP (2) JP6999903B2 (da)
KR (1) KR102608158B1 (da)
CN (2) CN108778285A (da)
AR (1) AR106505A1 (da)
AU (1) AU2016344737C1 (da)
BR (1) BR112018008496A2 (da)
CA (1) CA3003076C (da)
DK (1) DK3368044T3 (da)
ES (1) ES2883282T3 (da)
GB (1) GB201518979D0 (da)
HU (1) HUE055778T2 (da)
IL (1) IL258876B (da)
LT (1) LT3368044T (da)
MA (2) MA54412A (da)
MX (2) MX384040B (da)
PL (1) PL3368044T3 (da)
RS (1) RS62764B1 (da)
RU (1) RU2745606C2 (da)
SI (1) SI3368044T1 (da)
TW (1) TWI791420B (da)
UY (1) UY36967A (da)
WO (1) WO2017072243A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3086045A1 (en) 2017-12-19 2019-06-27 Akouos, Inc. Aav-mediated delivery of therapeutic antibodies to the inner ear
EP3829546A1 (en) 2018-08-02 2021-06-09 Hospital Sant Joan de Deu Immediate release formulation of a triple combination of active pharmaceutical ingredients useful in the treatment of polycystic ovary syndrome
EP4007814A1 (en) 2019-07-26 2022-06-08 Akouos, Inc. Methods of treating hearing loss using a secreted target protein
EP3842803A1 (en) * 2019-12-23 2021-06-30 Katholieke Universiteit Leuven Cxcl14 in polycystic ovary syndrome
KR20230041965A (ko) 2020-05-13 2023-03-27 아카우오스, 인크. Slc26a4-연관 청력손실을 치료하기 위한 조성물 및 방법
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
CN117157108A (zh) 2020-12-29 2023-12-01 阿库斯股份有限公司 用于治疗clrn1相关听力损失和/或视力损失的组合物和方法
AR128422A1 (es) 2022-02-02 2024-05-08 Akouos Inc Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
AU2001239826B2 (en) * 2000-02-23 2006-06-15 Orentreich Foundation For The Advancement Of Science, Inc. Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
GB0106565D0 (en) * 2001-03-16 2001-05-09 Leuven K U Res & Dev Growth hormone treatment
GB0108863D0 (en) * 2001-04-10 2001-05-30 Leuven K U Res & Dev Combinational therapy
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
WO2004052390A1 (en) * 2002-12-11 2004-06-24 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
GB0702537D0 (en) * 2007-02-12 2007-03-21 Leuven K U Res & Dev Treatment for excessive adiposity
CN103845342A (zh) * 2012-12-03 2014-06-11 浙江大学 治疗青春期多囊卵巢综合征合并胰岛素抵抗的组合药物
US10474539B1 (en) * 2015-12-18 2019-11-12 EMC IP Holding Company LLC Browsing federated backups
EP3829546A1 (en) * 2018-08-02 2021-06-09 Hospital Sant Joan de Deu Immediate release formulation of a triple combination of active pharmaceutical ingredients useful in the treatment of polycystic ovary syndrome

Also Published As

Publication number Publication date
MX2018005252A (es) 2018-09-18
RS62764B1 (sr) 2022-01-31
RU2745606C2 (ru) 2021-03-29
KR20180098234A (ko) 2018-09-03
MA54412A (fr) 2021-11-10
MA43106B1 (fr) 2021-09-30
WO2017072243A8 (en) 2018-03-22
AU2016344737B2 (en) 2021-07-08
MX2021007976A (es) 2021-08-16
HUE055778T2 (hu) 2021-12-28
CN108778285A (zh) 2018-11-09
AU2016344737A9 (en) 2018-08-09
EP3368044B1 (en) 2021-06-09
JP2022009374A (ja) 2022-01-14
WO2017072243A1 (en) 2017-05-04
BR112018008496A2 (pt) 2018-10-23
IL258876B (en) 2022-03-01
JP2019501113A (ja) 2019-01-17
RU2018119146A (ru) 2019-11-28
MA43106A (fr) 2021-05-05
US20240000804A1 (en) 2024-01-04
US20190060328A1 (en) 2019-02-28
EP3368044A1 (en) 2018-09-05
TW201720432A (zh) 2017-06-16
JP6999903B2 (ja) 2022-02-04
AU2016344737C1 (en) 2021-10-07
EP3892281A3 (en) 2021-11-10
AU2016344737A1 (en) 2018-05-17
CA3003076A1 (en) 2017-05-04
EP3892281A2 (en) 2021-10-13
GB201518979D0 (en) 2015-12-09
MX384040B (es) 2025-03-14
TWI791420B (zh) 2023-02-11
UY36967A (es) 2017-05-31
PL3368044T3 (pl) 2021-12-20
WO2017072243A9 (en) 2018-07-26
AR106505A1 (es) 2018-01-24
CN117379440A (zh) 2024-01-12
ES2883282T3 (es) 2021-12-07
SI3368044T1 (sl) 2022-05-31
RU2018119146A3 (da) 2020-02-25
CA3003076C (en) 2023-12-05
LT3368044T (lt) 2021-10-25
IL258876A (en) 2018-06-28
KR102608158B1 (ko) 2023-11-29

Similar Documents

Publication Publication Date Title
DK3851537T5 (da) Behandling af hyperbilirubinæmi
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3302565T3 (da) Faste doseringsformer af palbociclib
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3180331T3 (da) Polymorfer af selinexor
DK3461891T3 (da) Nedstrømsbehandling af en alkalisk phosphatase
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3102555T3 (da) Sammensætninger af forbindelser og anvendelser deraf
DK3458052T3 (da) Kombinationsbehandling af cancer
DK3307267T3 (da) Behandling af multipel sklerose
DK3132009T3 (da) Fremgangsmåde
DK3283210T3 (da) Fremgangsmåde
DK3474822T3 (da) Formuleringer af brincidofovir
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3418273T3 (da) Derivater af flavagliner
HUE055778T2 (hu) Oligo-ovulációval összefüggõ májzsírosodás kezelése
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK3511000T3 (da) Krystallinsk form x2 af grapiprant
DK3289363T3 (da) Specifik påvisning af clusterin isoformer
DK3201323T3 (da) Modificering af bakteriofag
IL254502A0 (en) Solid forms of menaquinols
DK3073409T3 (da) Maskering af forskellige indholdstyper
DK3430004T3 (da) Faststofformer af nilotinibsalte
DK3173071T3 (da) Formularing af maropitant